In non-diabetic AD cases, MAP2 mRNA levels were reduced 3.3-fold (p = 0.018), GFAP levels were increased 2-fold (p = 0.036), and AIF1 levels remained unchanged (p = 0.329) compared to non-diabetic NCI controls (Fig. 4C). The gene discussed is MAP2; the disease is Alzheimer disease.